Among possible pathogenic and adaptive mechanism of acute myocardial infarction and development of its complications, the system of prostanoids, particularly prostacycline-thromboxane system is of prime importance. But many questions relating the role of prostacycline-thromboxane system in pathogenesis of myocardial infarction associated with heart failure have studied insufficiently. The objective of this work is to study the ststus of prostacycline-thromboxane system in patients of acute myocardial infarction associated with heart failure and its correlation with the platelet functions depending on stages of heart failure. 
Introduction
Myocardial infarction is the most widespread disease causing high percentage of invalidity and mortality. 1 . Among all cardiovascular diseases, it is the most dangerous as it causes more sick rate, disability and mortality. Prognosis and severity of myocardial infarction to a considerable extent are related to the after effects of illness, which appear during the first days of the disease 2 , and result in death. Fifty percent cases may occur due to complication of heart failure 3, 4 .
Despite considerable achievements in the field of pathogenesis of heart failure, not all the pathogenic mechanisms have been studied till now and for that reason there is a little progress in its treatment. Among possible pathogenic and adaptive mechanism of acute myocardial infarction and development of its complications, the system of prostanoids, particularly prostacyclinethromboxane system is of prime importance 5 . Discovery of prostacycline-thromboxane system permits to study the pathogenesis of coronary atherosclerosis, ischemic heart disease and myocardial infarction and to propose some ideas concerning the participation of this system in the pathogenesis of heart failure as well 6.7 .
It has been shown previously that among the causes of the development of heart failure associated with acute myocardial infarction, the main role belongs to the clinical specification of the disease i.e. depth and extension and the localization of the infarction, the nature of infarction i,e, primary or repeated attacks of the disease 4 . However, many questions relating the role of prostacyclinethromboxane system in pathogenesis of myocardial infarction associated with heart failure have studied insufficiently, though it is known that the value of prostacycline-thromboxane effect is determined by their quantitative ratio. The later is caused by intensity of their byosynthesis and metabolism in lungs, vessels, platelets and other tissues 8, 9 .
Prostacycline and thromboxane-B2 are metabolites of 20 poly-unsaturated carbon fatty acids-the main regulators of vascular platelet interaction 10 . M S Muller et al made an attempt to characterize platelet function at acute myocardial infarction as well as local and systemic factors that may influence on their status under such conditions 11 . Action of powerful anti-platelet factor of prostacycline on platelet during acute myocardial infarction has been studied as well. The prostaglandin bears particular interest, because it is the most powerful anti-aggregating substance and has powerful endogenous protective action against micro-thrombus formation during acute myocardial infarction 12 .
The main objective of this work is to study the ststus of prostacycline-thromboxane system in patients of acute myocardial infarction associated with heart failure and its correlation with the platelet functions depending on stages of heart failure.
Methods and Materials
This study was performed as a part of the dissertation in the department of Internal Medicine, Hospital no. 27 in Kharkov State Medical Institute, Ukraine in 1987-89. In the coronary care unit and in intensive care unit, 120 patients with acute myocardial infarction were studied.
The status of prostacycline-thromboxane was considered by the level of stable metabolites of prostacycline and thromboxane -A2 as 6-keto-PGF and TXB2 respectively in venous plasma. 6-Keto-PGF-1α and TXB2 levels were determined by Radio-immunological method with the help of kits manufactured by the English Firm "New England Nuclear". The blood samples were drawn from subclavian or cubital veins into the cooled silico-glass or propylene test tubes which contained EDTA anticoagulant for determination of prostanoids in the serum according to Morris's recommendations.
To determine the platelet aggregation, the instrument "Bian-120" transmitter ( GVRBorn's method 13 ) was used. The blood was taken from the subclavian or cubital veins into the plastic tubes with 3.8% solution of sodium citrate at the rate of 9:1. Aggregation action of platelet was determined by "Bian-120" transmitter and measurer permitting to graphically dropping of optical density in the aggregation process.
Results
Among the selected patients, only 6 were women. Their age and sex distribution are shown in the table 1. TheMaximum 51 (42.5%) patients were of age between 50-59 years. According to the classification of acute heart failure by M J Wolk, S Scheidt, Killip 14 , all studied patients were divided into four stages of heart failure (Table II) . Among them 23 (19.1%) without symptoms of heart failure were referred to the stage I; 47 (39.2%) patients having signs of marked heart failure and crept or rales as less than 50% surface of both lungs were included into the stage II. 
The respondents were distributed according to the localization of their MI. Of them anterior infarction was 53 (44.2%), antero-lateral was 32(26.7%), antero-septal was 21(17.5%), antero-inferior was 5 (4.2%), and inferior was 6 (5.0%), Their distribution was shown according to their stages. (Table 1I ) Table III showed that prostacycline level was highest when symptoms of heart failure was absent at 1 st stage and lowest at the 4 th stage. Thromboxane (TXB2) level was higher in 3 rd and 4 th stages than in stages I and II. The more prominent is imbalance ratio, the severe is the acute heart failure; i.e. predominance of thromboxane link in the system. The degree of imbalance was lineally increased up to the III stage but reduced somewhat at 4 th stage, what supports the role of the system in the pathogenesis of pulmonary edema.
Microcirculation status was evaluated according to platelet aggregation (Table IV) . Platelet aggregation rate was somewhat higher in II stage but lowest in cardiac asthma where in pulmonary oedema, this parameter did not differ from I& II stages. Clear dependence was found in analyzing platelet index values which was decreasing as heart failure becoming more and more severe. Platelet refraction index was directly proportional to the stages of acute heart failure.
Dynamics of parameters of prostacycline -thromboxane system were analyzed on the 1-2, 3-4, 5-7 and 10-12 days in patients with Acute MI according to the stages of heart failure (table V) . During I stage, 6-ketoPGF-1a level from 1 st to 4 th days was actually unchanged. Up to 7 th day, these values significantly increased and then decreased to the initial level to the end of 12 th day. TXB2 level had found reverse tendency. In 2 nd stge, 6-ketoPGF-1a level had behaved same as Ist stage but increasing TXB2 level was found initially and then decreasing at the 12 th day. Balance of TXb2/6-ketoPG-1a was raised on the 1 st day and after that found decreased only a little bit.
During III stage of heart failure with cardiac asthma, 6-ketoPGF-1a level was lowest on 3-4 days and then found increased. TXB2 level was found same as 6-ketoPGF-1a and their ratio was high initially and then somewhat decreased up to 10-12 days. At the 3rd stage of heart failure with pulmonary edema, TXB2 level was found highest during 1-2 days and both parameters were sharply reduced up to the 10 th -12 th days where TXB2 reduced mre than 6-ketoPGF-1a. In this process their ratio level reached equal to one.
Together with the dynamic change of prostacyclinethromboxane system, there was an analysis study about the change of functional platelet activity during the period of MI depending on the progression of heart failure ( Table  VI) . At the stage I of heart failure, platelet aggregation rate level was the highest during up to 3-4 days. It was reduced by 1/3 and up to 5-7 days, it returned to original state. But at 10-12 days, this value sharply reduced and equals 2 times lower than original level. Platelet aggregation index and its corresponding refraction index remained same up to 4 th day, after that aggregation index increased in 5-7 days but refraction index increased, which occurred on the basis of increasing level of aggregation rate. Up to 10-12 days, aggregation index significantly reduced and refraction index increased.
The 2 nd stage of heart failure was characterized by more significant delaying in dynamics and by stabilizing of platelet aggregation index. Aggregation rate was only somewhat reduced with little variations up to 12 th day. At the same time aggregation rate and aggregation index did not change during this period. At the 3 rd stage, during cardiac asthma aggregation rate reduced at 5-7 days then increased up to 10-12 days but refraction index had reduced tendency while refraction index increasing. At the 3 rd stage with pulmonary edema, aggregation rate was somewhat stable and aggregation index had a tendency to reduction but refraction index to increase. 
Discussion
Prostacycline level was inversely proportional to the stages of heart failure but thromboxane level and their imbalance ratio were directly proportional (Table III) . Their levels were higher in pulmonary edema than that in cardiogenic shock. Such evidences support the role of thromboxane in the pathogenesis of pulmonary edema.
Microcirculation status was evaluated according to platelet aggregation parameters. Because of little quantity of patients having acute myocardial infarction with 4 th stage of cardiogenic shock, parameters of these group of patients were not performed (Table IV) . Functional platelet properties showed that they influence on those parameters like aggregation and refraction but not on aggregation rate.
Dynamics in prostacycline and thromboxane found increased day by day but decreased at 10-12 days in I and II stages but in 3 rd stage with cardiac asthma, they increased up to10-12 days. Balance ratio obtained to the maximum on the 1st days of disease and after that found decreased only in every stages (Table V) . But in pulmonary edema it increased at 5-7days and deceased at 10-12 days which might be related to the exhausted compensatory potential of the system during acute period of the disease.
Analyzing indices of platelet aggregation potential in patients having acute MI, table VI showed that the severe the heart failure, higher was the refraction index. Character of aggregation index variations had been of particular importance. If during the 1 st and 2 nd stages it varied about definite mean value, during 3 rd stage with pulmonary edema it gradually reduced. Less informative was aggregation rate. The severe was the heart failure; less was aggregation rate.
Comparing parameters of prostacycline-thromboxane system and platelet aggregation ability in case of acute heart failure seemed the fact that higher is the thromboxane level and imbalance ratio, higher is the platelet refraction index and lower is the aggregation index.
Results of this study worked out close interconnection between dynamic changes of prostacycline-thromboxane system and the platelet aggregation potential in patients with acute myocardial infarction depending on the stages of heart failure.
Acute myocardial infarction complicated with acute heart failure is characterized by activation of prostacycline thromboxane system which is expressed in progressive reduction of prostacycline level and increase of thromboxane level in venous blood as heart failure becomes more severe. Imbalance ratio of prostacyclinethromboxane system is formed by progressive deterioration of heart failure.
Parameters of platelet aggregation function and prostacycline thromboxane system were interrelated during the stages of heart failure. It was observed that there was an increase of platelet refraction index, where as aggregation rate did not change, but aggregation index was increased in patients with acute myocardial infarction without complication of heart failure i.e. at first stage.
During managing of patients with acute myocardial infarction, it seems to be expedient to investigate the parameters of prostacycline thromboxane system and platelet aggregation in different stages of heart failure to follow up the prognosis of acute heart failure and to select the proper therapy.
